Luca Issi
Stock Analyst at RBC Capital
(1.43)
# 3,400
Out of 4,905 analysts
202
Total ratings
38.4%
Success rate
-12.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $5 → $4 | $2.77 | +44.40% | 8 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $1.25 | +700.00% | 9 | May 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $21 → $18 | $19.47 | -7.55% | 7 | May 8, 2025 | |
| MRNA Moderna | Maintains: Sector Perform | $32 → $28 | $31.26 | -10.43% | 17 | May 2, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $205 → $210 | $169.90 | +23.60% | 2 | May 2, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $24 → $20 | $4.15 | +381.93% | 5 | Mar 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $310 → $330 | $320.53 | +2.95% | 27 | Mar 21, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $105 → $95 | $13.50 | +603.70% | 7 | Mar 19, 2025 | |
| SGMO Sangamo Therapeutics | Reiterates: Sector Perform | $2 | $0.51 | +292.00% | 6 | Mar 18, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | $17 | $11.33 | +50.04% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $8.61 | +50.99% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $15 | $10.91 | +37.49% | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $4.22 | +729.38% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $20.75 | +25.30% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $41.75 | +67.66% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $57.29 | +22.19% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $53 → $48 | $65.13 | -26.30% | 13 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $16.76 | +150.60% | 8 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $14.99 | +60.11% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $33.32 | +71.07% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $8.16 | +267.65% | 9 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $33.76 | +98.46% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $9.02 | +398.89% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.76 | +44.93% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $26.31 | +192.66% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $8.34 | +79.86% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $12.06 | +347.76% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.05 | +582.93% | 5 | Aug 7, 2024 |
Adverum Biotechnologies
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.77
Upside: +44.40%
Allogene Therapeutics
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.25
Upside: +700.00%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $19.47
Upside: -7.55%
Moderna
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $31.26
Upside: -10.43%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $205 → $210
Current: $169.90
Upside: +23.60%
Lexeo Therapeutics
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $4.15
Upside: +381.93%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Outperform
Price Target: $310 → $330
Current: $320.53
Upside: +2.95%
Korro Bio
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $13.50
Upside: +603.70%
Sangamo Therapeutics
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.51
Upside: +292.00%
Ocular Therapeutix
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $11.33
Upside: +50.04%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $8.61
Upside: +50.99%
Mar 4, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $10.91
Upside: +37.49%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $4.22
Upside: +729.38%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $20.75
Upside: +25.30%
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $41.75
Upside: +67.66%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $57.29
Upside: +22.19%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $53 → $48
Current: $65.13
Upside: -26.30%
Feb 11, 2025
Reiterates: Outperform
Price Target: $42
Current: $16.76
Upside: +150.60%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $14.99
Upside: +60.11%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $33.32
Upside: +71.07%
Jan 21, 2025
Reiterates: Outperform
Price Target: $30
Current: $8.16
Upside: +267.65%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $33.76
Upside: +98.46%
Jan 14, 2025
Reiterates: Outperform
Price Target: $45
Current: $9.02
Upside: +398.89%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.76
Upside: +44.93%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $26.31
Upside: +192.66%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $8.34
Upside: +79.86%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $12.06
Upside: +347.76%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.05
Upside: +582.93%